LIFE (losartan intervention for endpoint reduction in hypertension) study and its substudies

International Congress Series

Volumn 1303, Issue , 2007, Pages 129-137

  Borghi, Claudio ^a   Ertek, Sibel ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b GÜVEN HOSPITAL   (Turkey)

Author keywords

Atenolol; Hypertension; Left ventricular hypertrophy; Losartan

Indexed keywords

EID: 34447633186     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2007.03.014     Document Type: Article

References (55)

1. Hajjar I., and Kotchen T. Trends in the prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. J. Am. Med. Assoc. 290 (2003) 199-206
2. JNC 7 writing committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J. Am. Med. Assoc. 289 (2003) 2560-2572
3. Rakugi H., et al. Induction of angiotensin converting enzyme in the neointima after vascular injury: possible role in restenosis. J. Clin. Invest. 93 (1994) 339-346
4. Viswanathan M., et al. Baloon angioplasty enhances the expression of angiotensin II AT1 receptors in neointima of rat aorta. J. Clin. Invest. 90 (1992) 1707-1712
5. Dazu V.J. Cell biology and genetics of angiotensin in cardiovascular disease. J. Hypertens. 12 suppl 4 (1994) S3-S10
6. Grote K., Drexler H., and Schieffer B. Renin-angiotensin system and atherosclerosis. Nephrol. Dial. Transplant. 19 (2004) 770-773
7. Wassmann S., and Nickenig G. Pathophysiological regulation of the AT 1-receptor and implications for vascular disease. J. Hypertens., Suppl. 24 (2006) S15-S21
8. Cheng Z.J., Vapaatalo H., and Mervaala E. Angiotensin II and vascular inflammation. Med. Sci. Monit. 11 (2005) RA194-RA205
9. Scheidegger K.J., Butler S., and Witztum J.L. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J. Biol. Chem. 272 (1997) 21609-21615
10. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting enzyme inhibitor, ramipril on cardiovascular events in high risk patients. N. Eng. J. Med. 342 (2000) 145-153
11. De Zeeuw D., et al. Renoprotective effects of rennin-angitensin system inhibitors. Lancet 367 (2006) 899-900
12. Chyrsant S.G., and Chyrsant G.S. The pleiotrophic effects of angiotensin receptor blockers. J. Clin. Hypertens. (Greenwich) 8 (2006) 261-268
13. Weber M.A. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. J. Hypertens. 15 (1997) S31-S36 (Suppl)
14. Elliot W.J. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr. Hypertens. Rep. 2 (2000) 402-411
15. Dahlöf B., et al. The losartan intervention for endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. Am. J. Hypertens. 10 (1997) 705-713
16. Kjeldsen S.E., et al. Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy. J. Clin. Hypertens. (Greenwich) 8 (2006) 487-492
17. Dahlöf B., et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am. J. Hypertens. 8 (1995) 578-583
18. Hasson L., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354 (1999) 1751-1756
19. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2 (1986) 57-66
20. Dahlöf B., et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
21. Dahlöf B., et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan intervention for endpoint reductions in hypertension. Hypertension 32 (1998) 989-997
22. Nemer M. Mechanisms of angiotensin II. Dependent progression to heart failure. Novartis Found. Symp. 274 (2006) 58-68
23. Yusuf S., et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril on cardiovascular events in high risk patients: the Heart Outcomes Prevention Evaluation study investigators. N. Engl. J. Med. 342 (2000) 145-153
24. Verdecchia P., et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 104 (2001) 2039-2044
25. Hasson L., et al. Effect of angiotensin-converting-enzyme-inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 353 (1999) 611-616
26. Lindholm L.H., et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
27. Ibsen H., et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45 (2005) 181-182
28. Ibsen H., et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J. Hypertens. 22 (2004) 1679-1681
29. Ibsen H., et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 29 (2006) 595-600
30. Gerdts E., et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the LIFE study. Hypertension 39 (2002) 739-743
31. Deverux R.B., et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292 (2004) 2396-2398
32. Li D., et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104 (2001) 2608-2614
33. Shi Y. Enalapril effects on atrial remodelling and atrial fibrillation in experimental congestive heart failure. Cardiovasc. Res. 54 (2002) 456-461
34. Kumagai K., et al. Effect of angiotensin II type 1 receptor antagonist on electrical and structural remodelling in atrial fibrillation. J. Am. Coll. Cardiol. 41 (2003) 2197-2204
35. Nakashima H., et al. Angiotensin II antagonist prevents electrical remodelling in atrial fibrillation. Circulation 101 (2000) 2612-2617
36. Kalus J.S., Coleman C.I., and White M. The impact of suppressing the rennin-angiotensin system on atrial fibrillation. J. Clin. Pharmacol. 46 (2006) 21-28
37. Madrid A.H., et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin. Electrophysiol. 27 (2004) 1405-1410
38. Healey J.S., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. 45 (2005) 1832-1839
39. Madrid A.H., et al. Prevention of recurrence in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J. Renin Angiotensin Aldosterone Syst. 5 (2004) 114-120
40. Madrid A.H., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106 (2002) 331-336
41. Ueng K.C., et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: results of a prospective and controlled study. Eur. Heart J. 24 (2003) 2090-2098
42. Stewart S., et al. A population-based study of the long-term risks associated with atrial fibrillation. 20 year follow-up of the Renfrew/Paisley Study. Am. J. Med. 113 (2002) 359-364
43. Vidaillet H., et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am. J. Med. 113 (2002) 365-367
44. Tsang T.S., et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. Am. J. Coll. Cardiol. 42 (2003) 93-100
45. Pedersen O.D., et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100 (1999) 376-380
46. Watchell K., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. The losartan intervention for endpoint reduction in hypertension (LIFE) study. J. Am. Coll. Cardiol. 45 (2005) 712-719
47. Gerdts E., et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the losartan intervention for endpoint reduction in hypertension (LIFE) study. Hypertension 39 (2002) 739-743
48. Benjamin E.J., et al. Left atrial size and the risk of stroke and death.The Framingham Heart study. Circulation 92 (1995) 835-841
49. Gottdiener J.S., et al. Effect of single drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 98 (1998) 140-148
50. Kizer J.R., et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomised to losartan versus atenolol: the losartan intervention for endpoint reduction in hypertension study. Hypertension 45 (2005) 46-52
51. Stier C.T., et al. Stroke prevention by losartan in stroke prone spontaneously hypertensive rats. J. Hypertens. 11 suppl. 3 (1993) S37-S42
52. Achard J.M., et al. Protection against ischemia: a physiological function of the renin-angiotensin system. Biochem. Pharmacol. 62 (2001) 261-271
53. Verdecchia P., et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 104 (2001) 2039-2044
54. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetic epidemic. Nature 414 (2001) 782-787
55. Lindholm L.H., et al. Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J. Hypertens. 20 (2002) 1879-1886